The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists
by

1 Answer

Answer :

B. It is a rectangular hyperbola
by

Related questions

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Description : The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Last Answer : B. It is a rectangular hyperbola

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Description : A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Last Answer : C. Competitive antagonist

A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Description : A drug which does not produce any action by itself but decreases the slope of the log dose-response curve and suppresses the maximal response to another drug is a: A. Physiological antagonist B. Competitive antagonist C. Noncompetitive antagonist D. Partial agonist

Last Answer : C. Noncompetitive antagonist

A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Description : A drug ‘R’ producing no response by itself causes the log dose-response curve of another drug ‘S’ to shift to the right in a parallel manner without decreasing the maximal response: Drug ‘R’ is a: A. Partial agonist B. Inverse agonist C. Competitive antagonist D. Noncompetitive antagonist

Last Answer : C. Competitive antagonist

The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Description : The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Last Answer : C. Suppression of maximal agonist response

The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Description : The following is not a feature of competitive antagonists: A. Chemical resemblance with the agonist B. Parallel rightward shift of the agonist log doseresponse curve C. Suppression of maximal agonist response D. Apparent reduction in agonist affinity for the receptor

Last Answer : C. Suppression of maximal agonist response

Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Description : Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Last Answer : A. Continuous use of agonists

Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Description : Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Last Answer : C. Both ligand recognition and signal transduction

The following statement is not true of ‘potency’ of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by the relative position of its dose-response curve on the dose axis C. It is often not a major consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Description : The following statement is not true of potency' of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by ... consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Last Answer : D. It reflects the capacity of the drug to produce a drastic response

The following statement is not true of ‘potency’ of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by the relative position of its dose-response curve on the dose axis C. It is often not a major consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Description : The following statement is not true of potency' of a drug: A. Refers to the dose of the drug needed to produce a certain degree of response B. Can be related to that of its congeners by ... consideration in the choice of a drug D. It reflects the capacity of the drug to produce a drastic response

Last Answer : D. It reflects the capacity of the drug to produce a drastic response

The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Description : The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Last Answer : D. Bicuculline

The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Description : The following is a competitive antagonist of GABA but a noncompetitive antagonist of diazepam: A. Picrotoxin B. Muscimol C. Flumazenil D. Bicuculline

Last Answer : D. Bicuculline

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Description : What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Last Answer : C. Agonists induce a conformational change in the receptoR

What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Description : What is true in relation to drug receptors: A. All drugs act through specific receptors B. All drug receptors are located on the surface of the target cells C. Agonists induce a conformational change in the receptor D. Partial agonists have low affinity for the receptor

Last Answer : C. Agonists induce a conformational change in the receptor

The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Description : The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Last Answer : B. Chemical antagonism

The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Description : The antidotal action of sodium nitrite in cyanide poisoning is based on: A. Physical antagonism B. Chemical antagonism C. Physiological antagonism D. Noncompetitive antagonism

Last Answer : B. Chemical antagonism

‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Description : ‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Last Answer : B. The maximal intensity of response that can be produced by the drug

In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Description : In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Last Answer : C. Inhalational

‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Description : ‘Drug efficacy’ refers to: A. The range of diseases in which the drug is beneficial B. The maximal intensity of response that can be produced by the drug C. The dose of the drug needed to produce half maximal effect D. The dose of the drug needed to produce therapeutic effect

Last Answer : B. The maximal intensity of response that can be produced by the drug

In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Description : In addition to slow intravenous infusion, which of the following routes of administration allows for titration of the dose of a drug with the response: A. Sublingual B. Transdermal C. Inhalational D. Nasal insufflation

Last Answer : C. Inhalational

Receptor agonists possess: A. Affinity but no intrinsic activity B. Intrinsic activity but no affinity C. Affinity and intrinsic activity with a + sign D. Affinity and intrinsic activity with a – sign

Description : Receptor agonists possess: A. Affinity but no intrinsic activity B. Intrinsic activity but no affinity C. Affinity and intrinsic activity with a + sign D. Affinity and intrinsic activity with a – sign

Last Answer : C. Affinity and intrinsic activity with a + sign

Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Description : Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Last Answer : D. Ocular β adrenergic blockers

Agonists affect the receptor molecule in the following manner: A. Alter its amino acid sequence B. Denature the receptor protein C. Alter its folding or alignment of subunits D. Induce covalent bond formation

Description : Agonists affect the receptor molecule in the following manner: A. Alter its amino acid sequence B. Denature the receptor protein C. Alter its folding or alignment of subunits D. Induce covalent bond formation

Last Answer : C. Alter its folding or alignment of subunits

Receptor agonists possess: A. Affinity but no intrinsic activity B. Intrinsic activity but no affinity C. Affinity and intrinsic activity with a + sign D. Affinity and intrinsic activity with a – sign

Description : Receptor agonists possess: A. Affinity but no intrinsic activity B. Intrinsic activity but no affinity C. Affinity and intrinsic activity with a + sign D. Affinity and intrinsic activity with a – sign

Last Answer : C. Affinity and intrinsic activity with a + sign

Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Description : Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Last Answer : D. Dependence of action on lipophilicity

Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Description : Drugs acting through receptors exhibit the following features except: A. Structural specificity B. High potency C. Competitive antagonism D. Dependence of action on lipophilicity

Last Answer : D. Dependence of action on lipophilicity

High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Description : High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Last Answer : D. Generally makes the drug long acting

High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Description : High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Last Answer : D. Generally makes the drug long acting

High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Description : High plasma protein binding: A. Increases volume of distribution of the drug B. Facilitates glomerular filtration of the drug C. Minimises drug interactions D. Generally makes the drug long acting

Last Answer : D. Generally makes the drug long acting

Which of the following statements is not true of fixed dose combination formulations: A. They are more convenient B. Contraindication to one of the components does not contraindicate the formulation C. The dose of any one component cannot be independently adjusted D. The time course of action of the different components may not be identical

Description : Which of the following statements is not true of fixed dose combination formulations: A. They are more convenient B. Contraindication to one of the components does not contraindicate the formulation ... adjusted D. The time course of action of the different components may not be identical

Last Answer : B. Contraindication to one of the components does not contraindicate the formulation

A demand curve is considered as Rectangular Hyperbola when : (a) e > 1 (b) e = 1 at all points (c) e < 1 (d) e = 0

Description : A demand curve is considered as Rectangular Hyperbola when : (a) e > 1 (b) e = 1 at all points (c) e < 1 (d) e = 0

Last Answer : (a) e > 1 (b) e = 1 at all points (c) e < 1 (d) e = 0

In comparison to inhaled β 2 adrenergic agonists, the inhaled anticholinergics: A. Are more effective in bronchial asthma B. Are better suited for control of an acute attack of asthma C. Produce slower response in bronchial asthma D. Produce little benefit in chronic obstructive lung disease

Description : In comparison to inhaled β 2 adrenergic agonists, the inhaled anticholinergics: A. Are more effective in bronchial asthma B. Are better suited for control of an acute attack of asthma C. Produce slower response in bronchial asthma D. Produce little benefit in chronic obstructive lung disease

Last Answer : C. Produce slower response in bronchial asthma

A heavy string attached at two ends at same horizontal level and when central dip is very small approaches the following curve (A) Catenary (B) Parabola (C) Hyperbola (D) Elliptical

Description : A heavy string attached at two ends at same horizontal level and when central dip is very small approaches the following curve (A) Catenary (B) Parabola (C) Hyperbola (D) Elliptical

Last Answer : (B) Parabola

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Description : Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Last Answer : A. Continuous use of agonists

Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Description : Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Last Answer : C. Both ligand recognition and signal transduction

Leukotriene antagonists are used in bronchial asthma: A. For terminating acute attacks B. As monotherapy in place of β2 agonists C. As adjuvants to β2 agonists for avoiding corticosteroids D. As nebulized powder in refractory cases

Description : Leukotriene antagonists are used in bronchial asthma: A. For terminating acute attacks B. As monotherapy in place of β2 agonists C. As adjuvants to β2 agonists for avoiding corticosteroids D. As nebulized powder in refractory cases

Last Answer : C. As adjuvants to β2 agonists for avoiding corticosteroids

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses

Choose the correct statement about allopurinol: A. It is a purine antimetabolite with antineoplastic activity B. It is a competitive inhibitor of xanthine oxidase C. It is inactive itself, but its metabolite alloxanthine is a competitive inhibitor of xanthine oxidase D. Both allopurinol as well as its metabolite alloxanthine are noncompetitive inhibitors of xanthine oxidase

Description : Choose the correct statement about allopurinol: A. It is a purine antimetabolite with antineoplastic activity B. It is a competitive inhibitor of xanthine oxidase C. It is inactive itself ... D. Both allopurinol as well as its metabolite alloxanthine are noncompetitive inhibitors of xanthine oxidase

Last Answer : B. It is a competitive inhibitor of xanthine oxidase

Benzodiazepines differ from barbiturates in the following aspects except: A. They have a steeper dose response curve B. They have higher therapeutic index C. They have lower abuse liability D. They do not induce microsomal drug metabolizing enzymes

Description : Benzodiazepines differ from barbiturates in the following aspects except: A. They have a steeper dose response curve B. They have higher therapeutic index C. They have lower abuse liability D. They do not induce microsomal drug metabolizing enzymes

Last Answer : A. They have a steeper dose response curve

The following is a competitive type of enzyme inhibitor: A. Acetazolamide B. Disulfiram C. Physostigmine D. Theophylline

Description : The following is a competitive type of enzyme inhibitor: A. Acetazolamide B. Disulfiram C. Physostigmine D. Theophylline

Last Answer : C. Physostigmine

Reflex bronchoconstriction is most likely to occur with the following form of inhaled antiasthma medication: A. Metered dose spray of drug in solution B. Dry powder rotacap C. Nebuliser D. Nebuliser with spacer

Description : Reflex bronchoconstriction is most likely to occur with the following form of inhaled antiasthma medication: A. Metered dose spray of drug in solution B. Dry powder rotacap C. Nebuliser D. Nebuliser with spacer

Last Answer : B. Dry powder rotacap

A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Description : A ‘toxic effect’ differs from a ‘side effect’ in that: A. It is not a pharmacological effect of the drug B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication C. It must involve drug induced cellular injury D. It involves host defence mechanisms

Last Answer : B. It is a more intense pharmacological effect that occurs at high dose or after prolonged medication